EGFR and lung cancer: It was recently studied on human lung cancer cells (NSCLC) with EGFR T790M mutation and was found to induce apoptosis in lung cancer cells via downregulation of activated Akt 51. In this study, we propose that indacaterol inhibits Akt-1, a newer mechanism of action as an anti-cancer agent.